Biogen Inc.'s decision to increase the patient size of its two ongoing Phase III studies of the potential Alzheimer's therapy, aducanumab, as specified in study protocol and without unblinding the studies, has worried investors, with the concerns coinciding with a sharp 6.6% drop in the company's share price on Nasdaq to $296.08 on Feb. 14, the day the changes were revealed.
Biogen Spooks With Phase III Aducanumab Changes
Recruiting more patients into a trial to retain statistical power is standard practice, but with other companies discontinuing late-stage investigational Alzheimer's therapies, the difficulty in maintaining confidence in the development of new therapies for the condition has been underlined by investor responses to Biogen's alterations.
More from Neurological
More from Therapy Areas
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.